Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide)

Drug Metabolism and Disposition

Volumn 42, Issue 7, 2014, Pages 1163-1173

  Tseng, Elaine ^a   Walsky, Robert L ^b,c   Luzietti Jr , Ricardo A ^b,d   Harris, Jennifer J ^b,e   Kosa, Rachel E ^a   Goosen, Theunis C ^a   Zientek, Michael A ^a   Obach, R Scott ^a  

^a PFIZER INC   (United States)

^b ASTRAZENECA   (United Kingdom)

^c EMD Serono Research Institute Inc   (United States)

^d Agilux Laboratories   (United States)

^e Experimental Station   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; BUSPIRONE; CILOSTAZOL; CYTOCHROME P450 3A4; CYTOCHROME P450 3A4 SELECTIVE INACTIVATOR; CYTOCHROME P450 3A5; CYTOCHROME P450 INHIBITOR; DRONEDARONE; EBASTINE; FELODIPINE; KETOCONAZOLE; MARAVIROC; MIDAZOLAM; NIFEDIPINE; NISOLDIPINE; OTENABANT; QUETIAPINE; QUININE; RIMONABANT; SAQUINAVIR; SIMVASTATIN; TACROLIMUS; TAMOXIFEN; TERFENADINE; TESTOSTERONE; TRIAZOLAM; UNCLASSIFIED DRUG; VARDENAFIL; VERAPAMIL; VINCRISTINE; CYTOCHROME P450 3A;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG CLEARANCE; DRUG METABOLISM; ENZYME KINETICS; ENZYME METABOLISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; IN VITRO STUDY; LIVER MICROSOME; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; CATALYSIS; DRUG EFFECTS; ENZYMOLOGY; METABOLISM;

CATALYSIS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME INHIBITORS; HUMANS; IN VITRO TECHNIQUES; MICROSOMES, LIVER;

EID: 84903176068     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.057000     Document Type: Article

References (64)

1. Anderson PL, Lamba J, Aquilante CL, Schuetz E, and Fletcher CV (2006) Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. Journal of Acquired Immune Deficiency Syndromes (1999) 42:441-449.
2. Anderson PL, Aquilante CL, Gardner EM, Predhomme J, McDaneld P, Bushman LR, Zheng JH, Ray M, and MaWhinney S (2009) Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother 64:1071-1079.
3. Bakken GV, Rudberg I, Christensen H, Molden E, Refsum H, and Hermann M (2009) Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos 37:254-258.
4. Barry A and Levine M (2010) A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients. Ther Drug Monit 32:708-714.
5. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, and Ni L, et al.; Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43:443-469.
6. Chen JS, Li LS, Cheng DR, Ji SM, Sun QQ, Cheng Z, Wen JQ, Sha GZ, and Liu ZH (2009) Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus. Transplant Proc 41:1557-1561.
7. de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, and Kuypers DR (2012) In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther 92:366-375.
8. de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, and Kuypers DR (2013) Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism. Pharmacogenomics 14:1467-1480.
9. Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, and Hall SD (2006) Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34:1317-1327.
10. Egbelakin A, Ferguson MJ, MacGill EA, Lehmann AS, Topletz AR, Quinney SK, Li L, McCammack KC, Hall SD, and Renbarger JL (2011) Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 56:361-367.
11. Elens L, Nieuweboer A, Clarke SJ, Charles KA, de Graan AJ, Haufroid V, Mathijssen RHJ, and van Schaik RHN (2013) CYP3A4 intron 6 C.T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics 14:137-149.
12. Evans WE and Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491.
13. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL, Jr, Bhat K, Kim RB, and Wilkinson GR (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13:595-606.
14. Fukuda T, Onishi S, Fukuen S, Ikenaga Y, Ohno M, Hoshino K, Matsumoto K, Maihara A, Momiyama K, Ito T, Fujio Y, and Azuma J (2004) CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. The Pharmacogenomics Journal 4:34-39.
15. Gibbs MA, Thummel KE, Shen DD, and Kunze KL (1999) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187.
16. Goosen TC, Walsky RL, Dickens M, Hyland R, Scott DO, Cronenberger C, Ravva P, Venkatakrishnan K, Wheeler J, Hyde CL, Chen M, Johnson KJ, Johnston G, and Banerjee P (2010) Influence of CYP3A5 genotype on CP-945,598 pharmacokinetics and weight loss in the treatment of obese subjects. 9th International ISSX Meeting, Online Abstracts; 2010 Sept 4-8; Istanbul, Turkey. Suppl 5, No 2. International Society for the Study of Xenobiotics, Washington, DC.
17. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R, Lim HL, Ong AB, and Lee HS (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 20:3683-3690.
18. Guilhaumou R, Solas C, Bourgarel-Rey V, Quaranta S, Rome A, Simon N, Lacarelle B, and Andre N (2011) Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. Cancer Chemother Pharmacol 68:1633-1638.
19. Guengerich FP(2005) Human cytochrome P450 enzymes. In: Cytochrome P450: Structure, Mechanism, and Biochemistry, 3rd ed. (Ortiz de Montellano PR, ed), pp. 377-530, Plenum Publishers, New York.
20. Haas DM, Quinney SK, Clay JM, Renbarger JL, Hebert MF, Clark S, Umans JG, Caritis SN, and Obstetric-Fetal Pharmacology Research Units N (2013) Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. American Journal of Perinatology 30:275-281.
21. Haufroid V, Wallemacq P, VanKerckhove V, Elens L, De Meyer M, Eddour DC, Malaise J, Lison D, and Mourad M. (2006) CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 6:2706-2713.
22. He P, Court MH, Greenblatt DJ, and Von Moltke LL (2005) Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clinical Pharmacology and Therapeutics 77:373-387.
23. Hesselink DA, van Schaik RHN, van der Heiden IP, van der Werf M, Gregoor PJHS, Lindemans J, Weimar W, and van Gelder T (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245-254.
24. Jin Y, Wang YH, Miao J, Li L, Kovacs RJ, Marunde R, Hamman MA, Philips S, Hilligoss J, and Hall SD (2007) Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. Clin Pharmacol Ther 82:579-585.
25. Josephson F, Allqvist A, Janabi M, Sayi J, Aklillu E, Jande M, Mahindi M, Burhenne J, Bottiger Y, Gustafsson LL, Haefeli WE, and Bertilsson L (2007) CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clinical Pharmacology and Therapeutics 81:708-712.
26. Kenworthy KE, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727.
27. Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, Whittington D, and Ensign D (2007) Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 82:410-426.
28. Kile DA, MaWhinney S, Aquilante CL, Rower JE, Castillo-Mancilla JR, and Anderson PL (2012) A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses 28:1227-1234.
29. Kim KA, Park PW, Lee OJ, Kang DK, and Park JY (2007) Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. Journal of Clinical Pharmacology 47:87-93.
30. Kim IW, Moon YJ, Ji E, Kim KI, Han N, Kim SJ, Shin WG, Ha J, Yoon JH, Lee HS, and Oh JM (2012) Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients. European Journal of Clinical Pharmacology 68:657-669.
31. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, and Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
32. Lalovic B, Phillips B, Risler LL, Howald W, and Shen DD (2004) Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 32:447-454.
33. Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294.
34. Langaee TY, Gong Y, Yarandi HN, Katz DA, Cooper-DeHoff RM, Pepine CJ, and Johnson JA (2007) Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin Pharmacol Ther 81:386-391.
35. Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, and Cusatis G, et al. (2005) Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res 11:7398-7404.
36. Li X, Jeso V, Heyward S, Walker GS, Sharma R, Micalizio GC, and Cameron MD (2014) Characterization of T-5 N-oxide formation as the first highly selective measure of CYP3A5 activity. Drug Metab Dispos 42:334-342.
37. Li X, Song X, Kamenecka TM, and Cameron MD (2012) Discovery of a highly selective CYP3A4 inhibitor suitable for reaction phenotyping studies and differentiation of CYP3A4 and CYP3A5. Drug Metab Dispos 40:1803-1809.
38. Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, and Watkins PB (2005) Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther 78:605-618.
39. Naito T, Takashina Y, Yamamoto K, Tashiro M, Ohnishi K, Kagawa Y, and Kawakami J (2011) CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. J Clin Pharmacol 51:1529-1538.
40. Nikisch G, Baumann P, Oneda B, Kiessling B, Weisser H, Mathe AA, Yoshitake T, Kehr J, Wiedemann G, and Eap CB (2011) Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. Journal of Psychopharmacology (Oxford, England) 25:896-907.
41. Niwa T, Murayama N, Emoto C, and Yamazaki H (2008) Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. Curr Drug Metab 9:20-33.
42. Park JY, Kim KA, Park PW, Lee OJ, Kang DK, Shon JH, Liu KH, and Shin JG (2006) Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin Pharmacol Ther 79:590-599.
43. Picard N, Rouguieg-Malki K, Kamar N, Rostaing L, and Marquet P (2011) CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. Transplantation 91:652-656.
44. Santoro AB, Struchiner CJ, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, and Suarez-Kurtz G (2013) CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients. Clinical Pharmacology and Therapeutics 94:201-202.
45. Savic RM, Barrail-Tran A, Duval X, Nembot G, Panhard X, Descamps D, Verstuyft C, Vrijens B, Taburet AM, and Goujard C, et al.; ANRS 134-COPHAR 3 Study Group (2012) Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients. Clin Pharmacol Ther 92:575-583.
46. Shih PS and Huang JD (2002) Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 30:1491-1496.
47. Shirasaka Y, Chang SY, Grubb MF, Peng CC, Thummel KE, Isoherranen N, and Rodrigues AD (2013) Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions. Drug Metab Dispos 41:1566-1574.
48. Shon JH, Ku HY, Bae SY, Oh MK, Yeo CW, Bae SK, and Shin JG (2011) The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. Pharmacogenet Genomics 21:820-828.
49. Solas C, Simon N, Drogoul MP, Quaranta S, Frixon-Marin V, Bourgarel-Rey V, Brunet C, Gastaut JA, Durand A, Lacarelle B, and Poizot-Martin I (2007) Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. British Journal of Clinical Pharmacology 64:353-362.
50. Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, Miura M, Suzuki T, Kato T, and Habuchi T (2005) Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 37:1730-1732.
51. Tomalik-Scharte D, Doroshyenko O, Kirchheiner J, Jetter A, Lazar A, Klaassen T, Frank D, Wyen C, Fätkenheuer G, and Fuhr U (2008) No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam. Eur J Clin Pharmacol 64:1033-1035.
52. Walsky RL and Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug metabolism and disposition: the biological fate of chemicals 32:647-660.
53. Walsky RL, Obach RS, Hyland R, Kang P, Zhou S, West M, Geoghegan KF, Helal CJ, Walker GS, and Goosen TC, et al. (2012) Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. Drug Metab Dispos 40:1686-1697.
54. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJJ, and Wilkinson GR (2000) CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B59-promoter region polymorphism. Clin Pharmacol Ther 68:82-91.
55. Wempe MF and Anderson PL (2011) Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment. Drug Metab Dispos 39:522-527.
56. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883-891.
57. Williams JA, Cook J, and Hurst SI (2003) A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos 31:1526-1530.
58. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, and Gurney H (2004) CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 75:529-538.
59. Yamamoto T, Kubota T, Ozeki T, Sawada M, Yokota S, Yamada Y, Kumagai Y, and Iga T (2005) Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem. Clinica Chimica Acta; International Journal of Clinical Chemistry 362:147-154.
60. Yoo HD, Park SA, Cho HY, and Lee YB (2009) Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects. Clinical Pharmacology and Therapeutics 86:281-284.
61. Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, and Liu KH, et al. (2004) Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 76:104-112.
62. Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, Lin YS, Shen DD, and Thummel KE (2012) Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition. Clinical Pharmacology and Therapeutics 92:737-745.
63. Zheng T, Su CH, Zhao J, Zhang XJ, Zhang TY, Zhang LR, Kan QC, and Zhang SJ (2013) Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects. Die Pharmazie 68:257-260.
64. Zhou Q, Ruan ZR, Jiang B, Yuan H, and Zeng S (2013) Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. Die Pharmazie 68:124-128.